(-)-Sparteine (BioDeep_00000171951)

Main id: BioDeep_00000002013

 

human metabolite PANOMIX_OTCML-2023 blood metabolite natural product


代谢物信息卡片


Pachycarpine Sulfate (1:1), Pentahydrate, (7S-(7alpha,7aalpha,14alpha,14abeta))-Isomer

化学式: C15H26N2 (234.2096)
中文名称: (-)-鹰爪豆碱
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: C1CCN2CC3CC(C2C1)CN4C3CCCC4
InChI: InChI=1S/C15H26N2/c1-3-7-16-11-13-9-12(14(16)5-1)10-17-8-4-2-6-15(13)17/h12-15H,1-11H2

描述信息

C - Cardiovascular system > C01 - Cardiac therapy > C01B - Antiarrhythmics, class i and iii > C01BA - Antiarrhythmics, class ia
D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents
D012102 - Reproductive Control Agents > D010120 - Oxytocics
(-)-Sparteine is a natural alkaloid isolated from beans.
(-)-Sparteine is a natural alkaloid isolated from beans.

同义名列表

35 个代谢物同义名

Pachycarpine Sulfate (1:1), Pentahydrate, (7S-(7alpha,7aalpha,14alpha,14abeta))-Isomer; Sparteine Monohydrochloride, (7R-(7alpha,7aalpha,14alpha,14abeta))-Isomer; Sparteine Monohydroiodide, (7R-(7alpha,7aalpha,14alpha,14abeta))-Isomer; Sparteine Sulfate (1:1), (7S-(7alpha,7aalpha,14alpha,14aalpha))-Isomer; Sparteine Hydrochloride, (7R-(7alpha,7aalpha,14alpha,14abeta))-Isomer; Sparteine Sulfate (1:1), (7S-(7alpha,7aalpha,14alpha,14abeta))-Isomer; Sparteine Hydrochloride, (7S-(7alpha,7aalpha,14alpha,14abeta))-Isomer; Sparteine Hydroiodide, (7R-(7alpha,7aalpha,14alpha,14abeta))-Isomer; Sparteine, (7S-(7alpha,7aalpha,14alpha,14aalpha))-Isomer; Sparteine, (7S-(7alpha,7aalpha,14alpha,14abeta))-Isomer; Sparteine, (7R-(7alpha,7aalpha,14alpha,14abeta))-Isomer; Sparteine, (7R-(7alpha,7abeta,14alpha,14abeta))-Isomer; Sparteine, (7S-(7alpha,7abeta,14alpha,14abeta))-Isomer; 7,15-diazatetracyclo[7.7.1.0²,⁷.0¹⁰,¹⁵]heptadecane; Sulfate Anhydrous, Sparteine; Anhydrous, Sparteine Sulfate; Sparteine sulfate anhydrous; Sparteine, (-)-Isomer; Sparteine, (+)-Isomer; genisteine-alkaloid; Genisteine Alkaloid; alpha-Isosparteine; alpha Isosparteine; beta-Isosparteine; beta Isosparteine; Sparteine sulfate; Depasan Retard; (-)-Sparteine; Pachycarpine; D-sparteine; L-Sparteine; Sparteine; (-)-Lupinidine; (-)-Sparteine; Sparteine



数据库引用编号

12 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

60 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。

亚细胞结构定位 关联基因列表
Cytoplasm 7 CNP, GCK, GRHPR, PMP2, PRL, PTTG1IP, RAC1
Peripheral membrane protein 2 CYP1B1, GCK
Endoplasmic reticulum membrane 2 CYP1B1, RAC1
Nucleus 6 GCK, PMP2, PRL, PTTG1IP, RAC1, RFC2
cytosol 5 GCK, GRHPR, LIPE, PMP2, RAC1
dendrite 1 RAC1
trans-Golgi network 1 RAC1
nucleoplasm 4 GCK, PRL, PTTG1IP, RFC2
RNA polymerase II transcription regulator complex 1 PRL
Cell membrane 2 LIPE, RAC1
Lipid-anchor 2 CNP, RAC1
Cytoplasmic side 1 RAC1
lamellipodium 1 RAC1
ruffle membrane 1 RAC1
Golgi apparatus membrane 1 GCK
Synapse 2 CNP, RAC1
cell cortex 1 RAC1
glutamatergic synapse 1 RAC1
Golgi membrane 1 GCK
mitochondrial inner membrane 1 CNP
postsynapse 1 RAC1
Cytoplasm, cytosol 1 LIPE
plasma membrane 2 ACVR1, RAC1
Membrane 6 ACVR1, CNP, CYP1B1, LIPE, PTTG1IP, RAC1
axon 1 CCK
basolateral plasma membrane 1 GCK
caveola 1 LIPE
extracellular exosome 5 CNP, GRHPR, PMP2, PTTG1IP, RAC1
extracellular space 3 CCK, CNP, PRL
perinuclear region of cytoplasm 1 CNP
mitochondrion 3 CYP1B1, GCK, GRHPR
intracellular membrane-bounded organelle 1 CYP1B1
Microsome membrane 1 CYP1B1
Single-pass type I membrane protein 2 ACVR1, PTTG1IP
Secreted 3 CCK, PRL, RAC1
extracellular region 3 CCK, PRL, RAC1
mitochondrial outer membrane 1 CNP
dendritic spine 1 RAC1
cytoplasmic vesicle 1 RAC1
apical part of cell 1 ACVR1
Cell projection, lamellipodium 1 RAC1
focal adhesion 1 RAC1
microtubule 1 CNP
peroxisomal matrix 1 GRHPR
chromatin 1 PRL
cytoskeleton 1 RAC1
cytoplasmic ribonucleoprotein granule 1 RAC1
Basolateral cell membrane 1 GCK
Recycling endosome membrane 1 RAC1
endosome lumen 1 PRL
microvillus 1 CNP
Lipid droplet 1 LIPE
Membrane, caveola 1 LIPE
Cell projection, dendrite 1 RAC1
Melanosome 2 CNP, RAC1
myelin sheath 1 PMP2
pseudopodium 1 CNP
secretory granule membrane 1 RAC1
ficolin-1-rich granule membrane 1 RAC1
NADPH oxidase complex 1 RAC1
catalytic complex 1 GRHPR
myelin sheath abaxonal region 1 CNP
myelin sheath adaxonal region 1 CNP
BMP receptor complex 1 ACVR1
activin receptor complex 1 ACVR1
Ctf18 RFC-like complex 1 RFC2
DNA replication factor C complex 1 RFC2


文献列表

  • C Kragelund, C Hansen, J Reibel, B Nauntofte, K Brosen, S B Jensen, L A Torpet. Can the genotype or phenotype of two polymorphic drug metabolising cytochrome P450-enzymes identify oral lichenoid drug eruptions?. Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology. 2010 Jul; 39(6):497-505. doi: 10.1111/j.1600-0714.2010.00897.x. [PMID: 20492431]
  • Takashi Ito, Motohiro Kato, Koji Chiba, Osamu Okazaki, Yuichi Sugiyama. Estimation of the interindividual variability of cytochrome 2D6 activity from urinary metabolic ratios in the literature. Drug metabolism and pharmacokinetics. 2010; 25(3):243-53. doi: 10.2133/dmpk.25.243. [PMID: 20610883]
  • Teresa Bobkiewicz-Kozłowska, Marzena Dworacka, Sebastian Kuczyński, Małgorzata Abramczyk, Renata Kolanoś, Waleria Wysocka, Pedro M Garcia Lopez, Hanna Winiarska. Hypoglycaemic effect of quinolizidine alkaloids--lupanine and 2-thionosparteine on non-diabetic and streptozotocin-induced diabetic rats. European journal of pharmacology. 2007 Jun; 565(1-3):240-4. doi: 10.1016/j.ejphar.2007.02.032. [PMID: 17379208]
  • Clive C Gay, Kip E Panter, Katrina L Mealey, John M Gay, Steven W Hjartarson, Ahmed Tibary, Ernie S Motteram, Terrie Wierenga, Lynn F James. Comparison of plasma disposition of alkaloids after lupine challenge in cattle that had given birth to calves with lupine-induced arthrogryposis or clinically normal calves. American journal of veterinary research. 2004 Nov; 65(11):1580-3. doi: 10.2460/ajvr.2004.65.1580. [PMID: 15566098]
  • F Kees, L Färber, M Bucher, G Mair, K Mörike, H Grobecker. Pharmacokinetics of therapeutic doses of tropisetron in healthy volunteers. British journal of clinical pharmacology. 2001 Dec; 52(6):705-7. doi: 10.1046/j.0306-5251.2001.01512.x. [PMID: 11736884]
  • E Baltes, R Coupez, H Giezek, G Voss, C Meyerhoff, M Strolin Benedetti. Absorption and disposition of levocetirizine, the eutomer of cetirizine, administered alone or as cetirizine to healthy volunteers. Fundamental & clinical pharmacology. 2001 Aug; 15(4):269-77. doi: 10.1046/j.1472-8206.2001.00035.x. [PMID: 11564134]
  • P L Lohmann, M L Rao, M Ludwig, E U Griese, U M Zanger, K Mörike, W Maier, M Bagli. Influence of CYP2D6 genotype and medication on the sparteine metabolic ratio of psychiatric patients. European journal of clinical pharmacology. 2001 Jul; 57(4):289-95. doi: 10.1007/s002280100299. [PMID: 11549206]
  • T K Bergmann, L Bathum, K Brosen. Duplication of CYP2D6 predicts high clearance of desipramine but high clearance does not predict duplication of CYP2D6. European journal of clinical pharmacology. 2001 May; 57(2):123-7. doi: 10.1007/s002280100284. [PMID: 11417443]
  • O Slanar, F Perlík, V Jirásek. Phenotype of cytochrome P450 CYP2D6 in patients with familial adenomatous polyposis. Methods and findings in experimental and clinical pharmacology. 2001 Apr; 23(3):145-7. doi: 10.1358/mf.2001.23.3.627948. [PMID: 11523314]
  • P Milejski, K Orzechowska-Juzwenko, J Kamienowski, E Horoch, P Niewiński, M Hurkacz, Z Rzemisławska. [Clinical significance of oxidation and acetylation genetic polymorphism in patients with Parkinson's disease]. Neurologia i neurochirurgia polska. 1999 Sep; 33(5):1015-24. doi: . [PMID: 10672554]
  • . Clomipramine dose-effect study in patients with depression: clinical end points and pharmacokinetics. Danish University Antidepressant Group (DUAG). Clinical pharmacology and therapeutics. 1999 Aug; 66(2):152-65. doi: 10.1016/s0009-9236(99)90053-x. [PMID: 10460069]
  • A Rostami-Hodjegan, H K Kroemer, G T Tucker. In-vivo indices of enzyme activity: the effect of renal impairment on the assessment of CYP2D6 activity. Pharmacogenetics. 1999 Jun; 9(3):277-86. doi: 10.1097/00008571-199906000-00002. [PMID: 10471059]
  • S Tsiodras, R K Shin, M Christian, L M Shaw, D A Sass. Anticholinergic toxicity associated with lupine seeds as a home remedy for diabetes mellitus. Annals of emergency medicine. 1999 Jun; 33(6):715-7. doi: NULL. [PMID: 10339689]
  • L Poulsen, L Riishede, K Brøsen, S Clemensen, S H Sindrup. Codeine in post-operative pain. Study of the influence of sparteine phenotype and serum concentrations of morphine and morphine-6-glucuronide. European journal of clinical pharmacology. 1998 Aug; 54(6):451-4. doi: 10.1007/s002280050491. [PMID: 9776433]
  • K Droll, K Bruce-Mensah, S V Otton, A Gaedigk, E M Sellers, R F Tyndale. Comparison of three CYP2D6 probe substrates and genotype in Ghanaians, Chinese and Caucasians. Pharmacogenetics. 1998 Aug; 8(4):325-33. doi: 10.1097/00008571-199808000-00006. [PMID: 9731719]
  • E U Griese, U M Zanger, U Brudermanns, A Gaedigk, G Mikus, K Mörike, T Stüven, M Eichelbaum. Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics. 1998 Feb; 8(1):15-26. doi: 10.1097/00008571-199802000-00003. [PMID: 9511177]
  • J Holomán, J Glasa, M Veningerová, V Prachar, M Lukácsová. [Genetic polymorphism in sparteine oxidation--occurrence in healthy volunteers in Slovakia]. Bratislavske lekarske listy. 1997 Feb; 98(2):86-90. doi: . [PMID: 9264814]
  • W D Paar, S Poche, J Gerloff, H J Dengler. Polymorphic CYP2D6 mediates O-demethylation of the opioid analgesic tramadol. European journal of clinical pharmacology. 1997; 53(3-4):235-9. doi: 10.1007/s002280050368. [PMID: 9476037]
  • L Poulsen, L Arendt-Nielsen, K Brøsen, S H Sindrup. The hypoalgesic effect of tramadol in relation to CYP2D6. Clinical pharmacology and therapeutics. 1996 Dec; 60(6):636-44. doi: 10.1016/s0009-9236(96)90211-8. [PMID: 8988065]
  • H Madsen, T S Hansen, K Brøsen. Imipramine metabolism in relation to the sparteine oxidation polymorphism--a family study. Pharmacogenetics. 1996 Dec; 6(6):513-9. doi: 10.1097/00008571-199612000-00004. [PMID: 9014200]
  • A Bozkurt, N E Basçi, A Işimer, A Sayal, S O Kayaalp. Metabolic ratios of four probes of CYP2D6 in Turkish subjects: a cross-over study. European journal of drug metabolism and pharmacokinetics. 1996 Oct; 21(4):309-14. doi: 10.1007/bf03189732. [PMID: 9074895]
  • T Yokoi, Y Kosaka, M Chida, K Chiba, H Nakamura, T Ishizaki, M Kinoshita, K Sato, F J Gonzalez, T Kamataki. A new CYP2D6 allele with a nine base insertion in exon 9 in a Japanese population associated with poor metabolizer phenotype. Pharmacogenetics. 1996 Oct; 6(5):395-401. doi: 10.1097/00008571-199610000-00003. [PMID: 8946471]
  • J C Ritchie, S C Mitchell, R L Smith, A Q Zhang. Use of site-specified tritium labelling to confirm the formation of 17-oxosparteine as a minor urinary metabolite of sparteine in man. Xenobiotica; the fate of foreign compounds in biological systems. 1996 Sep; 26(9):977-82. doi: 10.3109/00498259609052499. [PMID: 8893044]
  • M C Robbins, D S Petterson, P G Brantom. A 90-day feeding study of the alkaloids of Lupinus angustifolius in the rat. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association. 1996 Aug; 34(8):679-86. doi: 10.1016/0278-6915(96)00040-3. [PMID: 8883468]
  • P Milejski, K Orzechowska-Juzwenko, J Pawlik, J Kamienowski, E Horoch, P Niewiński, M Hurkacz. [Clinical significance of the determination of oxidation and acetylation phenotype in patients with multiple sclerosis]. Neurologia i neurochirurgia polska. 1996 Jul; 30(4):571-9. doi: NULL. [PMID: 9045059]
  • J P Kévorkian, C Michel, U Hofmann, E Jacqz-Aigrain, H K Kroemer, M N Peraldi, M Eichelbaum, P Jaillon, C Funck-Brentano. Assessment of individual CYP2D6 activity in extensive metabolizers with renal failure: comparison of sparteine and dextromethorphan. Clinical pharmacology and therapeutics. 1996 May; 59(5):583-92. doi: 10.1016/s0009-9236(96)90187-3. [PMID: 8646830]
  • L Poulsen, K Brøsen, L Arendt-Nielsen, L F Gram, K Elbaek, S H Sindrup. Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects. European journal of clinical pharmacology. 1996; 51(3-4):289-95. doi: 10.1007/s002280050200. [PMID: 9010701]
  • U Jeppesen, L F Gram, K Vistisen, S Loft, H E Poulsen, K Brøsen. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. European journal of clinical pharmacology. 1996; 51(1):73-8. doi: 10.1007/s002280050163. [PMID: 8880055]
  • S H Sindrup, U Hofmann, J Asmussen, G Mikus, K Brøsen, F Nielsen, S H Ingwersen, C Broen Christensen. Impact of quinidine on plasma and cerebrospinal fluid concentrations of codeine and morphine after codeine intake. European journal of clinical pharmacology. 1996; 49(6):503-9. doi: 10.1007/bf00195938. [PMID: 8706777]
  • D Pelclová, J Mráz, V Patzelová, J Pícková, J Pospísil, L Vodicková, M Hornychová, J Vejlupková. Oxidative phenotype polymorphism (P450 2D6) and metabolism of toluene. International journal of clinical pharmacology and therapeutics. 1996 Jan; 34(1):38-42. doi: NULL. [PMID: 8688995]
  • J C Ritchie, S C Mitchell, R L Smith. Sparteine metabolism in a Nigerian population. Drug metabolism and drug interactions. 1996; 13(2):129-35. doi: 10.1515/dmdi.1996.13.2.129. [PMID: 8905244]
  • S H Sindrup, K Brøsen. The pharmacogenetics of codeine hypoalgesia. Pharmacogenetics. 1995 Dec; 5(6):335-46. doi: 10.1097/00008571-199512000-00001. [PMID: 8845855]
  • T Ebner, C O Meese, M Eichelbaum. Mechanism of cytochrome P450 2D6-catalyzed sparteine metabolism in humans. Molecular pharmacology. 1995 Dec; 48(6):1078-86. doi: NULL. [PMID: 8848008]
  • K Mörike, S Magadum, T Mettang, E U Griese, C Machleidt, U Kuhlmann. Propafenone in a usual dose produces severe side-effects: the impact of genetically determined metabolic status on drug therapy. Journal of internal medicine. 1995 Nov; 238(5):469-72. doi: 10.1111/j.1365-2796.1995.tb01225.x. [PMID: 7595187]
  • M F Fromm, U Hofmann, E U Griese, G Mikus. Dihydrocodeine: a new opioid substrate for the polymorphic CYP2D6 in humans. Clinical pharmacology and therapeutics. 1995 Oct; 58(4):374-82. doi: 10.1016/0009-9236(95)90049-7. [PMID: 7586928]
  • H Madsen, K K Nielsen, K Brøsen. Imipramine metabolism in relation to the sparteine and mephenytoin oxidation polymorphisms--a population study. British journal of clinical pharmacology. 1995 Apr; 39(4):433-9. doi: 10.1111/j.1365-2125.1995.tb04473.x. [PMID: 7640151]
  • N E Basci, K Brosen, A Bozkurt, A Isimer, A Sayal, S O Kayaalp. S-mephenytoin, sparteine and debrisoquine oxidation: genetic polymorphisms in a Turkish population. British journal of clinical pharmacology. 1994 Nov; 38(5):463-5. doi: 10.1111/j.1365-2125.1994.tb04383.x. [PMID: 7893589]
  • K K Nielsen, K Brøsen, M G Hansen, L F Gram. Single-dose kinetics of clomipramine: relationship to the sparteine and S-mephenytoin oxidation polymorphisms. Clinical pharmacology and therapeutics. 1994 May; 55(5):518-27. doi: 10.1038/clpt.1994.65. [PMID: 8181196]
  • M Veningerová, V Prachar, M Lukácsová, J Glasa, J Holomán. Rapid determination of sparteine and its metabolites in urine. Journal of chromatography. 1993 Dec; 622(2):274-7. doi: 10.1016/0378-4347(93)80277-b. [PMID: 8150877]
  • H Yokota, S Tamura, H Furuya, S Kimura, M Watanabe, I Kanazawa, I Kondo, F J Gonzalez. Evidence for a new variant CYP2D6 allele CYP2D6J in a Japanese population associated with lower in vivo rates of sparteine metabolism. Pharmacogenetics. 1993 Oct; 3(5):256-63. doi: 10.1097/00008571-199310000-00005. [PMID: 8287064]
  • K Brøsen, E Skjelbo, H Flachs. Proguanil metabolism is determined by the mephenytoin oxidation polymorphism in Vietnamese living in Denmark. British journal of clinical pharmacology. 1993 Aug; 36(2):105-8. doi: 10.1111/j.1365-2125.1993.tb04204.x. [PMID: 8398577]
  • E Koyama, Y Kikuchi, H Echizen, K Chiba, T Ishizaki. Simultaneous high-performance liquid chromatography-electrochemical detection determination of imipramine, desipramine, their 2-hydroxylated metabolites, and imipramine N-oxide in human plasma and urine: preliminary application to oxidation pharmacogenetics. Therapeutic drug monitoring. 1993 Jun; 15(3):224-35. doi: 10.1097/00007691-199306000-00009. [PMID: 8333003]
  • L F Gram, K Brøsen. Moclobemide treatment causes a substantial rise in the sparteine metabolic ratio. Danish University Antidepressant Group. British journal of clinical pharmacology. 1993 Jun; 35(6):649-52. doi: 10.1111/j.1365-2125.1993.tb04196.x. [PMID: 8329293]
  • H Yoshino, Y Hattori, H Imai, H Narabayashi, K Chiba. [Sparteine oxidation by hepatic cytochrome P-450 in patients with Parkinson's disease]. Rinsho shinkeigaku = Clinical neurology. 1993 Mar; 33(3):261-5. doi: . [PMID: 8334787]
  • E Skjelbo, L F Gram, K Brøsen. The N-demethylation of imipramine correlates with the oxidation of S-mephenytoin (S/R-ratio). A population study. British journal of clinical pharmacology. 1993 Mar; 35(3):331-4. doi: NULL. [PMID: 8471415]
  • S H Sindrup, K Brøsen, M G Hansen, T Aaes-Jørgensen, K F Overø, L F Gram. Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. Therapeutic drug monitoring. 1993 Feb; 15(1):11-7. doi: 10.1097/00007691-199302000-00002. [PMID: 8451774]
  • K Brøsen, J G Hansen, K K Nielsen, S H Sindrup, L F Gram. Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. European journal of clinical pharmacology. 1993; 44(4):349-55. doi: 10.1007/bf00316471. [PMID: 8513845]
  • V K Piotrovskiĭ, V G Belolipetskaia, D O Rumiantsev, V I Metelitsa. [The polymorphism of pachycarpine oxidation]. Eksperimental'naia i klinicheskaia farmakologiia. 1992 Jul; 55(4):56-8. doi: NULL. [PMID: 1458193]
  • P M Mrozikiewicz. [Clinical aspects of the polymorphism of oxidation phenotype]. Polski tygodnik lekarski (Warsaw, Poland : 1960). 1992 Jul; 47(27-28):608-10. doi: NULL. [PMID: 1488339]
  • S H Sindrup, K Brøsen, L F Gram. Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism. Clinical pharmacology and therapeutics. 1992 Mar; 51(3):288-95. doi: 10.1038/clpt.1992.24. [PMID: 1531951]
  • S H Sindrup, K Brøsen, L F Gram, J Hallas, E Skjelbo, A Allen, G D Allen, S M Cooper, G Mellows, T C Tasker. The relationship between paroxetine and the sparteine oxidation polymorphism. Clinical pharmacology and therapeutics. 1992 Mar; 51(3):278-87. doi: 10.1038/clpt.1992.23. [PMID: 1531950]
  • J Pospísil, V Patzelová, B Máca. New evidence of sparteine metabolites in humans. Drug metabolism and disposition: the biological fate of chemicals. 1992 Mar; 20(2):330-2. doi: NULL. [PMID: 1352230]
  • K K Nielsen, K Brøsen, L F Gram. Steady-state plasma levels of clomipramine and its metabolites: impact of the sparteine/debrisoquine oxidation polymorphism. Danish University Antidepressant Group. European journal of clinical pharmacology. 1992; 43(4):405-11. doi: 10.1007/bf02220617. [PMID: 1451721]
  • J H Schellens, H Ghabrial, H H van der Wart, E N Bakker, G R Wilkinson, D D Breimer. Differential effects of quinidine on the disposition of nifedipine, sparteine, and mephenytoin in humans. Clinical pharmacology and therapeutics. 1991 Nov; 50(5 Pt 1):520-8. doi: 10.1038/clpt.1991.177. [PMID: 1934865]
  • F Broly, N Vandamme, C Libersa, M Lhermitte. The metabolism of mexiletine in relation to the debrisoquine/sparteine-type polymorphism of drug oxidation. British journal of clinical pharmacology. 1991 Oct; 32(4):459-66. doi: 10.1111/j.1365-2125.1991.tb03931.x. [PMID: 1958440]
  • K Brøsen, T Zeugin, U A Meyer. Role of P450IID6, the target of the sparteine-debrisoquin oxidation polymorphism, in the metabolism of imipramine. Clinical pharmacology and therapeutics. 1991 Jun; 49(6):609-17. doi: 10.1038/clpt.1991.77. [PMID: 2060250]
  • S A Ward, N A Helsby, E Skjelbo, K Brøsen, L F Gram, A M Breckenridge. The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism--a panel study. British journal of clinical pharmacology. 1991 Jun; 31(6):689-92. doi: 10.1111/j.1365-2125.1991.tb05594.x. [PMID: 1867963]
  • K Clasen, L Madsen, K Brøsen, K Albøge, S Misfeldt, L F Gram. Sparteine and mephenytoin oxidation: genetic polymorphisms in east and west Greenland. Clinical pharmacology and therapeutics. 1991 Jun; 49(6):624-31. doi: 10.1038/clpt.1991.79. [PMID: 2060251]
  • P Petersen, K Brøsen. [Severe nortriptyline poisoning in poor metabolizers of the sparteine type]. Ugeskrift for laeger. 1991 Feb; 153(6):443-4. doi: . [PMID: 2000655]
  • J H Schellens, P A Soons, J H van der Wart, J W Hoevers, D D Breimer. Lack of pharmacokinetic interaction between nifedipine, sparteine and phenytoin in man. British journal of clinical pharmacology. 1991 Feb; 31(2):175-8. doi: 10.1111/j.1365-2125.1991.tb05508.x. [PMID: 2049233]
  • A Herchuelz, D Gangji, F Derenne, J P Jeanniot, J Douchamps. Metabolism of almitrine in extensive and poor metabolisers of debrisoquine/sparteine. British journal of clinical pharmacology. 1991 Jan; 31(1):73-6. doi: 10.1111/j.1365-2125.1991.tb03859.x. [PMID: 2015173]
  • A S Gross, G Mikus, C Fischer, M Eichelbaum. Polymorphic flecainide disposition under conditions of uncontrolled urine flow and pH. European journal of clinical pharmacology. 1991; 40(2):155-62. doi: 10.1007/bf00280070. [PMID: 1906003]
  • S H Sindrup, K Brøsen, P Bjerring, L Arendt-Nielsen, U Larsen, H R Angelo, L F Gram. Codeine increases pain thresholds to copper vapor laser stimuli in extensive but not poor metabolizers of sparteine. Clinical pharmacology and therapeutics. 1990 Dec; 48(6):686-93. doi: 10.1038/clpt.1990.212. [PMID: 2249379]
  • K Ganzler, I Szinai, A Salgó. Effective sample preparation method for extracting biologically active compounds from different matrices by a microwave technique. Journal of chromatography. 1990 Nov; 520(?):257-62. doi: 10.1016/0021-9673(90)85109-9. [PMID: 2086582]
  • S H Sindrup, L F Gram, T Skjold, E Grodum, K Brøsen, H Beck-Nielsen. Clomipramine vs desipramine vs placebo in the treatment of diabetic neuropathy symptoms. A double-blind cross-over study. British journal of clinical pharmacology. 1990 Nov; 30(5):683-91. doi: 10.1111/j.1365-2125.1990.tb03836.x. [PMID: 2271367]
  • S H Sindrup, K Brøsen, L F Gram. Nonlinear kinetics of imipramine in low and medium plasma level ranges. Therapeutic drug monitoring. 1990 Sep; 12(5):445-9. doi: 10.1097/00007691-199009000-00007. [PMID: 2293406]
  • J Moncrieff. Simultaneous determination of sparteine and its 2-dehydro and 5-dehydro metabolites in urine by high-performance liquid chromatography with electrochemical detection. Journal of chromatography. 1990 Jul; 529(1):194-200. doi: 10.1016/s0378-4347(00)83822-0. [PMID: 2211932]
  • M Manns, U Zanger, G Gerken, K F Sullivan, K H Meyer zum Büschenfelde, U A Meyer, M Eichelbaum. Patients with type II autoimmune hepatitis express functionally intact cytochrome P-450 db1 that is inhibited by LKM-1 autoantibodies in vitro but not in vivo. Hepatology (Baltimore, Md.). 1990 Jul; 12(1):127-32. doi: 10.1002/hep.1840120120. [PMID: 2373473]
  • W E Haefeli, M J Bargetzi, F Follath, U A Meyer. Potent inhibition of cytochrome P450IID6 (debrisoquin 4-hydroxylase) by flecainide in vitro and in vivo. Journal of cardiovascular pharmacology. 1990 May; 15(5):776-9. doi: 10.1097/00005344-199005000-00013. [PMID: 1692938]
  • M D Nielsen, K Brøsen, L F Gram. A dose-effect study of the in vivo inhibitory effect of quinidine on sparteine oxidation in man. British journal of clinical pharmacology. 1990 Mar; 29(3):299-304. doi: 10.1111/j.1365-2125.1990.tb03639.x. [PMID: 2310654]
  • K Brøsen, F Davidsen, L F Gram. Quinidine kinetics after a single oral dose in relation to the sparteine oxidation polymorphism in man. British journal of clinical pharmacology. 1990 Feb; 29(2):248-53. doi: 10.1111/j.1365-2125.1990.tb03628.x. [PMID: 2306418]
  • A Chaudhuri, W J Keller. New mammalian metabolites of sparteine. Life sciences. 1990; 47(4):319-25. doi: 10.1016/0024-3205(90)90590-n. [PMID: 2388532]
  • M Eichelbaum, A S Gross. The genetic polymorphism of debrisoquine/sparteine metabolism--clinical aspects. Pharmacology & therapeutics. 1990; 46(3):377-94. doi: 10.1016/0163-7258(90)90025-w. [PMID: 2188269]
  • Y Horai, J Taga, T Ishizaki, K Ishikawa. Correlations among the metabolic ratios of three test probes (metoprolol, debrisoquine and sparteine) for genetically determined oxidation polymorphism in a Japanese population. British journal of clinical pharmacology. 1990 Jan; 29(1):111-5. doi: 10.1111/j.1365-2125.1990.tb03609.x. [PMID: 2297455]
  • C Köppel, J Tenczer, I Arndt. Metabolic disposition of ajmaline. European journal of drug metabolism and pharmacokinetics. 1989 Oct; 14(4):309-16. doi: 10.1007/bf03190117. [PMID: 2633926]
  • L F Gram, K Brøsen, P Kragh-Sørensen, P Christensen. Steady-state plasma levels of E- and Z-10-OH-nortriptyline in nortriptyline-treated patients: significance of concurrent medication and the sparteine oxidation phenotype. Therapeutic drug monitoring. 1989 Sep; 11(5):508-14. doi: 10.1097/00007691-198909000-00003. [PMID: 2815225]
  • G Mikus, A S Gross, J Beckmann, R Hertrampf, U Gundert-Remy, M Eichelbaum. The influence of the sparteine/debrisoquin phenotype on the disposition of flecainide. Clinical pharmacology and therapeutics. 1989 May; 45(5):562-7. doi: 10.1038/clpt.1989.73. [PMID: 2498026]
  • J H Schellens, J H van der Wart, M Brugman, D D Breimer. Influence of enzyme induction and inhibition on the oxidation of nifedipine, sparteine, mephenytoin and antipyrine in humans as assessed by a "cocktail" study design. The Journal of pharmacology and experimental therapeutics. 1989 May; 249(2):638-45. doi: . [PMID: 2724144]
  • A Drøhse, L Bathum, K Brøsen, L F Gram. Mephenytoin and sparteine oxidation: genetic polymorphisms in Denmark. British journal of clinical pharmacology. 1989 May; 27(5):620-5. doi: 10.1111/j.1365-2125.1989.tb03426.x. [PMID: 2757884]
  • L F Gram, D Debruyne, V Caillard, J P Boulenger, J Lacotte, M Moulin, E Zarifian. Substantial rise in sparteine metabolic ratio during haloperidol treatment. British journal of clinical pharmacology. 1989 Feb; 27(2):272-5. doi: 10.1111/j.1365-2125.1989.tb05362.x. [PMID: 2713222]
  • P Kintz, A Tracqui, P Mangin, A Lugnier, A Chaumont. Subnanogram GC/NPD method for the determination of sparteine in biological fluids. Methods and findings in experimental and clinical pharmacology. 1989 Feb; 11(2):115-8. doi: . [PMID: 2709917]
  • K Brøsen, L F Gram. Quinidine inhibits the 2-hydroxylation of imipramine and desipramine but not the demethylation of imipramine. European journal of clinical pharmacology. 1989; 37(2):155-60. doi: 10.1007/bf00558224. [PMID: 2792169]
  • K Brøsen, L F Gram. Clinical significance of the sparteine/debrisoquine oxidation polymorphism. European journal of clinical pharmacology. 1989; 36(6):537-47. doi: 10.1007/bf00637732. [PMID: 2570698]
  • W D Paar, H Schuhler, R Fimmers, H J Dengler. Sparteine oxidation polymorphism: phenotyping by measurement of sparteine and its dehydrometabolites in plasma. European journal of clinical pharmacology. 1989; 36(6):555-60. doi: 10.1007/bf00637735. [PMID: 2590312]
  • T Ebner, C O Meese, M Eichelbaum. Thin-layer chromatographic screening test for polymorphic sparteine oxidation. Therapeutic drug monitoring. 1989; 11(2):214-6. doi: 10.1097/00007691-198903000-00016. [PMID: 2718225]
  • J H Schellens, H H van der Wart, J W Hoevers, D D Breimer. Gas chromatographic determination of sparteine and 2- and 5-dehydrosparteine in plasma and urine. Journal of chromatography. 1988 Sep; 431(1):203-9. doi: 10.1016/s0378-4347(00)83086-8. [PMID: 3235532]
  • Y Horai, T Ishizaki, M Eichelbaum, K Hashimoto, K Chiba, H J Dengler. Further analysis of sparteine oxidation in a Japanese population and comparison with data observed in different ethnic populations. Xenobiotica; the fate of foreign compounds in biological systems. 1988 Sep; 18(9):1077-84. doi: 10.3109/00498258809042230. [PMID: 3227705]
  • D W Clark, I R Edwards. Adverse drug reaction reporting and retrospective phenotyping for oxidation polymorphism. Medical toxicology and adverse drug experience. 1988 May; 3(3):241-7. doi: 10.1007/bf03259884. [PMID: 3398777]
  • T D Arias, L F Jorge, D Lee, R Barrantes, T Inaba. The oxidative metabolism of sparteine in the Cuna Amerindians of Panama: absence of evidence for deficient metabolizers. Clinical pharmacology and therapeutics. 1988 Apr; 43(4):456-65. doi: 10.1038/clpt.1988.58. [PMID: 3356089]
  • G Paolisso, S Sgambato, N Passariello, G Pizza, R Torella, P Tesauro, M Varricchio, F D'Onofrio. Plasma glucose lowering effect of sparteine sulphate infusion in non-insulin dependent (type 2) diabetic subjects. European journal of clinical pharmacology. 1988; 34(3):227-32. doi: 10.1007/bf00540948. [PMID: 3396617]
  • F Wagner, E Jähnchen, D Trenk, M Eichelbaum, P Harnasch, G Hauf, H Roskamm. Severe complications of antianginal drug therapy in a patient identified as a poor metabolizer of metoprolol, propafenone, diltiazem, and sparteine. Klinische Wochenschrift. 1987 Dec; 65(24):1164-8. doi: 10.1007/bf01733250. [PMID: 3437726]
  • T Ishizaki, M Eichelbaum, Y Horai, K Hashimoto, K Chiba, H J Dengler. Evidence for polymorphic oxidation of sparteine in Japanese subjects. British journal of clinical pharmacology. 1987 Apr; 23(4):482-5. doi: 10.1111/j.1365-2125.1987.tb03080.x. [PMID: 3580254]
  • S Sgambato, G Paolisso, N Passariello, M Varricchio, F D'Onofrio. Effect of sparteine sulphate upon basal and nutrient-induced insulin and glucagon secretion in normal man. European journal of clinical pharmacology. 1987; 32(5):477-80. doi: 10.1007/bf00637673. [PMID: 3305040]
  • K Brøsen, S V Otton, L F Gram. Imipramine demethylation and hydroxylation: impact of the sparteine oxidation phenotype. Clinical pharmacology and therapeutics. 1986 Nov; 40(5):543-9. doi: 10.1038/clpt.1986.221. [PMID: 3769385]
  • S Sgambato, N Passariello, G Paolisso, V Bisesti, P Tesauro. Effect of sparteine sulfate on insulin secretion in normal men. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. 1986 Oct; 18(10):686-8. doi: 10.1055/s-2007-1012407. [PMID: 3536704]
  • K Brøsen. Sparteine oxidation polymorphism in Greenlanders living in Denmark. British journal of clinical pharmacology. 1986 Oct; 22(4):415-9. doi: 10.1111/j.1365-2125.1986.tb02911.x. [PMID: 3768256]
  • E Jacqz, S D Hall, R A Branch. Genetically determined polymorphisms in drug oxidation. Hepatology (Baltimore, Md.). 1986 Sep; 6(5):1020-32. doi: 10.1002/hep.1840060534. [PMID: 3758933]
  • M Van der Graaff, N P Vermeulen, M C Koperdraat, D D Breimer. Non-linear pharmacokinetics of sparteine in the rat. Archives internationales de pharmacodynamie et de therapie. 1986 Aug; 282(2):181-95. doi: NULL. [PMID: 3767526]
  • M Eichelbaum, S Mineshita, E E Ohnhaus, C Zekorn. The influence of enzyme induction on polymorphic sparteine oxidation. British journal of clinical pharmacology. 1986 Jul; 22(1):49-53. doi: 10.1111/j.1365-2125.1986.tb02879.x. [PMID: 3741726]